ProCE Banner Activity

How I Select Frontline Treatment in Metastatic Melanoma

Clinical Thought
Here are my thoughts on key considerations when selecting frontline therapy for patients with metastatic melanoma, including when targeted therapy may be preferred over immunotherapy, factors that affect the selection of single-agent or combination immunotherapy, and when to discontinue immunotherapy.

Released: February 17, 2021

Expiration: February 16, 2022

Share

Faculty

Allison Betof Warner

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Allison Betof Warner, MD, PhD

Assistant Professor of Medicine (Oncology)
Director, Melanoma Medical Oncology Program
Director, Solid Tumor Cellular Therapy 
Leader, Melanoma & Cutaneous Oncology Clinical Research Group
Stanford University School of Medicine
Stanford, California

Allison Betof Warner, MD, PhD, has disclosed that she has received consulting fees from BluePath Solutions, Iovance, Nanobiotix, and Novartis.